Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Intercept Pharmaceuticals	Chimerix	ZIOPHARM Oncology	VBI Vaccines	Veru
Symbol	NASDAQ:ICPT	NASDAQ:CMRX	NASDAQ:ZIOP	NASDAQ:VBIV	NASDAQ:VERU
Price Information
Current Price	$18.21	$8.15	$3.10	$2.73	$7.48
52 Week Range	Hold	Buy	Hold	Buy	Buy
MarketRank™
Overall Score	2.2	1.7	1.3	1.5	1.4
Analysis Score	4.1	4.5	3.2	3.6	3.5
Community Score	3.1	2.4	2.4	3.2	2.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	3.3	1.7	0.8	0.8	0.0
Earnings & Valuation Score	0.6	0.0	0.0	0.0	0.6
Analyst Ratings
Consensus Recommendation	Hold	Buy	Hold	Buy	Buy
Consensus Price Target	$42.83	$18.80	$5.60	$7.00	$19.20
% Upside from Price Target	135.18% upside	130.67% upside	80.65% upside	156.41% upside	156.68% upside
Trade Information
Market Cap	$562.10 million	$690.55 million	$641.31 million	$671.08 million	$531.43 million
Beta	1.85	1.88	2.28	2.14	0.71
Average Volume	1,151,894	1,015,797	2,496,076	5,974,380	3,602,063
Sales & Book Value
Annual Revenue	$252 million	$12.52 million	$150,000.00	$2.22 million	$42.59 million
Price / Sales	2.40	56.12	4,447.57	312.59	12.63
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$1.57 per share	$1.79 per share	$0.52 per share	$0.50 per share	$0.43 per share
Price / Book	11.60	4.55	5.96	5.46	17.40
Profitability
Net Income	$-344,680,000.00	$-112,580,000.00	$-117,800,000.00	$-54,810,000.00	$-18,970,000.00
EPS	($10.89)	($0.86)	($0.34)	($0.46)	($0.11)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-106.64%	-321.31%	N/A	-2,837.73%	-44.55%
Return on Equity (ROE)	-1,973.10%	-36.57%	-48.49%	-36.69%	-23.72%
Return on Assets (ROA)	-48.51%	-33.53%	-43.53%	-28.29%	-13.80%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	0.10%	N/A
Current Ratio	3.44%	12.18%	10.12%	9.06%	1.83%
Quick Ratio	3.44%	12.18%	10.12%	8.95%	1.38%
Ownership Information
Institutional Ownership Percentage	85.77%	45.41%	48.00%	52.13%	23.32%
Insider Ownership Percentage	23.70%	9.00%	2.30%	10.50%	26.10%
Miscellaneous
Employees	498	54	103	127	339
Shares Outstanding	33.16 million	86.21 million	215.21 million	254.20 million	71.91 million
Next Earnings Date	8/9/2021 (Estimated)	8/9/2021 (Estimated)	8/5/2021 (Estimated)	7/30/2021 (Estimated)	5/12/2021 (Confirmed)
Optionable	Optionable	Optionable	Optionable	Optionable	Optionable

Source	Headline
	What Makes ING (ING) a Good Fit for "Trend Investing" - Nasdaq nasdaq.com - May 11 at 1:32 PM
	My Plea to Investors Right Now - Nasdaq nasdaq.com - May 10 at 8:57 PM
	Builders FirstSource (BLDR) Buys John's Lumber, Boosts Presence - Nasdaq nasdaq.com - May 10 at 3:55 PM
	Why Veru (VERU) Might Surprise This Earnings Season - Yahoo Finance finance.yahoo.com - May 10 at 3:55 PM
	Why Veru (VERU) Might Surprise This Earnings Season finance.yahoo.com - May 10 at 3:55 PM
	Where Does Veru Inc (VERU) Stock Fall in the Biotechnology Field After It Is Down -11.76% This Week? - InvestorsObserver investorsobserver.com - May 7 at 5:39 PM
	Veru (NASDAQ:VERU) Trading 8.6% Higher americanbankingnews.com - May 7 at 12:56 PM
	Veru Inc. (NASDAQ:VERU) Forecasted to Earn FY2022 Earnings of $0.00 Per Share americanbankingnews.com - May 7 at 11:35 AM
	Veru (NASDAQ:VERU) Stock Price Down 11.9% americanbankingnews.com - May 6 at 1:54 PM
	Premarket Mover: Veru Inc (VERU) Up 14.56% - InvestorsObserver investorsobserver.com - May 6 at 8:53 AM
	$14.36 Million in Sales Expected for Veru Inc. (NASDAQ:VERU) This Quarter americanbankingnews.com - May 6 at 4:48 AM
	Clinical News: MDMA and Therapy Significantly Benefits PTSD Patients and More - BioSpace biospace.com - May 5 at 5:52 PM
	Veru (VERU) Stock Rises After Enobosarm Shows Clinical Benefits in Phase 2 Trial - InvestorsObserver investorsobserver.com - May 5 at 5:52 PM
	Veru Inc. (VERU) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance finance.yahoo.com - May 5 at 5:52 PM
	Veru Inc. (VERU) Expected to Beat Earnings Estimates: Should You Buy? finance.yahoo.com - May 5 at 5:52 PM
	Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021 - Yahoo Finance finance.yahoo.com - May 5 at 12:51 PM
	Veru Announces the Presentation of Positive Phase 2 Clinical Data of Enobosarm in AR+ER+HER2- Metastatic Breast Cancer Patients that Have Progressed on Estrogen Blocking Agents and CDK 4/6 Inhibitor at the ESMO Breast Cancer Congress 2021 finance.yahoo.com - May 5 at 12:51 PM
	Veru's Stock Jumps As Enobosarm Shows Clinical Benefit In Heavily Pretreated Breast Cancer Patients finance.yahoo.com - May 5 at 12:51 PM
	Veru (NASDAQ:VERU) Shares Gap Up to $8.70 americanbankingnews.com - May 5 at 12:05 PM
	Veru (VERU) to Release Quarterly Earnings on Wednesday americanbankingnews.com - May 5 at 6:58 AM
	Will Top-Line Growth Buoy Motorola's (MSI) Q1 Earnings? - Nasdaq nasdaq.com - May 4 at 1:20 PM
	Vitum að staðan er flókin mbl.is - May 4 at 8:19 AM
	-$0.03 Earnings Per Share Expected for Veru Inc. (NASDAQ:VERU) This Quarter americanbankingnews.com - May 4 at 2:12 AM
	Veru Inc. (NASDAQ:VERU)’s Share Price Fell Recently, Although No Trouble Is On The Horizon stocksregister.com - May 3 at 2:54 PM
	Veru to Report Fiscal 2021 Second-Quarter Financial Results, Host Conference Call on May 12th - Yahoo Finance finance.yahoo.com - April 28 at 11:43 PM

Date	Company	Brokerage	Action
5/10/2021	Intercept Pharmaceuticals	Oppenheimer	Lower Price Target
5/7/2021	Intercept Pharmaceuticals	The Goldman Sachs Group	Lower Price Target
5/7/2021	Intercept Pharmaceuticals	Raymond James	Lower Price Target
5/7/2021	Intercept Pharmaceuticals	BMO Capital Markets	Lower Price Target
5/7/2021	Intercept Pharmaceuticals	Cantor Fitzgerald	Lower Price Target
5/6/2021	Intercept Pharmaceuticals	Stifel Nicolaus	Lower Price Target
3/18/2021	Intercept Pharmaceuticals	HC Wainwright	Upgrade
3/8/2021	Intercept Pharmaceuticals	Wedbush	Lower Price Target
3/8/2021	Intercept Pharmaceuticals	Needham & Company LLC	Lower Price Target
3/1/2021	Intercept Pharmaceuticals	B. Riley	Lower Price Target
3/1/2021	Intercept Pharmaceuticals	Chardan Capital	Lower Price Target
1/15/2021	Intercept Pharmaceuticals	Bank of America	Downgrade
12/21/2020	Intercept Pharmaceuticals	Jefferies Financial Group	Downgrade
11/11/2020	Intercept Pharmaceuticals	Canaccord Genuity	Boost Price Target
11/10/2020	Intercept Pharmaceuticals	Royal Bank of Canada	Lower Price Target
5/5/2021	Chimerix	Maxim Group	Initiated Coverage
4/12/2021	Chimerix	Jonestrading	Reiterated Rating
5/9/2019	Chimerix	Cowen	Reiterated Rating
3/6/2019	Chimerix	Citigroup	Lower Price Target
6/21/2020	ZIOPHARM Oncology	Laidlaw	Reiterated Rating
12/14/2020	Veru	Brookline Capital Management	Boost Price Target
3/20/2019	Veru	CIBC	Initiated Coverage

(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources